KR101387825B1 - process of manufacturing a bean sorce - Google Patents
process of manufacturing a bean sorce Download PDFInfo
- Publication number
- KR101387825B1 KR101387825B1 KR1020120038445A KR20120038445A KR101387825B1 KR 101387825 B1 KR101387825 B1 KR 101387825B1 KR 1020120038445 A KR1020120038445 A KR 1020120038445A KR 20120038445 A KR20120038445 A KR 20120038445A KR 101387825 B1 KR101387825 B1 KR 101387825B1
- Authority
- KR
- South Korea
- Prior art keywords
- cheonggukjang
- red ginseng
- weight
- parts
- mixing
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 244000046052 Phaseolus vulgaris Species 0.000 title abstract description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 title abstract description 3
- 238000000034 method Methods 0.000 title description 2
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 47
- 244000068988 Glycine max Species 0.000 claims abstract description 30
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 30
- 238000002156 mixing Methods 0.000 claims abstract description 21
- 235000013311 vegetables Nutrition 0.000 claims abstract description 19
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims abstract description 8
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 8
- 241001454694 Clupeiformes Species 0.000 claims abstract description 8
- 240000000599 Lentinula edodes Species 0.000 claims abstract description 8
- 235000019513 anchovy Nutrition 0.000 claims abstract description 8
- 238000005406 washing Methods 0.000 claims abstract description 8
- 244000291564 Allium cepa Species 0.000 claims abstract 2
- 238000001035 drying Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000004927 clay Substances 0.000 claims description 4
- 108010083364 chungkookjang Proteins 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 241000208340 Araliaceae Species 0.000 description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 description 8
- 235000008434 ginseng Nutrition 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 241000234282 Allium Species 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 208000002249 Diabetes Complications Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021257 carbohydrate digestion Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L23/00—Soups; Sauces; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/34—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging foodstuffs or other articles intended to be cooked or heated within the package
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/02—Antioxidant
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Mechanical Engineering (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Agronomy & Crop Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 5분 즉석 홍삼 청국장의 제조방법에 관한 것으로서, 더욱 상세하게는 물에 표고버섯, 양파, 다시마 및 멸치를 혼합하여 삶아서 야채 육수를 제조한 다음 청국장을 제조하기 위한 콩을 세척한 후 상기 야채 육수에서 불린 콩을 삶아서 숙성시켜 건조시킨 청국장 90 내지 98 중량%에 홍삼 2 내지 10 중량%를 혼합하여 제조된 5분 즉석 홍삼 청국장의 제조방법에 관한 것이다.The present invention relates to a manufacturing method of instant red ginseng Cheonggukjang for 5 minutes, and more specifically, after mixing boiled shiitake mushrooms, onions, kelp and anchovies to prepare vegetable broth and then washing the beans for preparing Cheonggukjang It relates to a manufacturing method of 5 minutes instant red ginseng Cheonggukjang prepared by mixing 2 to 10% by weight of red ginseng to 90 to 98% by weight of boiled soybeans soaked in vegetable broth and dried.
Description
본 발명은 5분 즉석 홍삼 청국장의 제조방법에 관한 것으로서, 더욱 상세하게는 물에 표고버섯, 양파, 다시마 및 멸치를 혼합하여 삶아서 야채 육수를 제조한 다음 청국장을 제조하기 위한 콩을 세척한 후 상기 야채 육수에서 불린 콩을 삶아서 숙성시켜 건조시킨 청국장에 홍삼을 혼합하여 제조된 즉석에서 끓여 먹을 수 있는 간편한 청국장이며 청국장의 맛을 그대로 살려서 즉석에서 신속하게 요리할 수 있는 5분 즉석 홍삼 청국장의 제조방법에 관한 것이다.The present invention relates to a manufacturing method of instant red ginseng Cheonggukjang for 5 minutes, and more specifically, after mixing boiled shiitake mushrooms, onions, kelp and anchovies to prepare vegetable broth and then washing the beans for preparing Cheonggukjang It is a simple Cheonggukjang made by mixing red ginseng with boiled soybeans mixed with boiled soybeans in vegetable broth and dried.The method of manufacturing instant red ginseng Cheonggukjang that can be cooked immediately with the taste of Cheonggukjang. It is about.
현대사회에서는 당뇨병을 포함한 만성 대사성 질환의 발병률이 급증하고 있다. 이는 의학발달에 따른 인간의 수명연장과 더불어 사회 경제적 환경의 변화로 인해 고열량식품 섭취 증가 및 운동량감소의 생활양식의 변화와 밀접한 관련이 있다. 과거 1970년대 초반, 인구의 1% 미만이던 당뇨병의 유병률이 최근 30세 이상의 성인을 대상으로 한 국내조사에서 10% 및 지역에 따라 13%에 육박하고 있으며, 50대 이상에서는 20% 정도의 유병률을 보이고 있는 실정이다. 여기에 잠재적인 위험군 (내당능장애, 임신성 당뇨병의 과거력 등)을 포함한다면 30대 이상에서 당대사질환의 유병률이 무려 20%에 달한다.In modern society, the incidence of chronic metabolic diseases including diabetes is increasing rapidly. This is closely related to the change of lifestyle of increasing high calorie food intake and reducing momentum due to the change of socioeconomic environment along with the life extension of humans due to medical development. In the early 1970s, the prevalence of diabetes, which was less than 1% of the population, was close to 10% and 13% by region in the recent survey of adults over 30 years of age. I'm showing you. Including these potential risk groups (such as impaired glucose tolerance, past history of gestational diabetes), the prevalence of glucose metabolic disease is more than 20% in people over 30 years of age.
전 세계적으로도 당뇨병 환자 수는 해마다 크게 증가하여 1995년에는 20세 이상 성인의 당뇨병 유병률이 4.0%였으나, 2025년에는 5.4%로 증가할 것으로 예측하고 있다. 또한 당뇨병은 전 세계 대부분 국가의 국민 건강을 위협하는 대표적 질병으로 WHO는 2005년 당뇨로 사망한 사람을 110만 명으로 추정하였고 이 수치는 과거 10년 전에 비해 50%나 증가한 수치이다. 더욱이 한국에서도 당뇨병에 의한 사망률이 연도별로 꾸준히 증가하여 한국인의 주요 사망원인의 하나를 차지하게 되었다. Globally, the number of diabetic patients is increasing year by year, and the prevalence of diabetes among adults aged 20 and over is 4.0% in 1995, but it is expected to increase to 5.4% by 2025. Diabetes is also a major threat to national health in most countries around the world. WHO estimates that 1.1 million people died of diabetes in 2005, an increase of 50% from the previous decade. Moreover, in Korea, the mortality rate from diabetes has steadily increased year by year, making it one of the leading causes of death in Korea.
우리나라 당뇨병의 특징 및 문제점은 당뇨병이 주로 노령인구에서 발생하는 서구와는 달리, 우리나라에서는 30~40대의 젊은 당뇨병환자가 급증하고 있다는 사실이다. 당뇨병은 유병기간이 길어질수록 만성 합병증에 의한 실명, 말기 신부전증, 신경질환, 하지 절단 및 감염질환 등이 급증하게 된다. 특히 당뇨 합병증으로서 뇌혈관질환 및 심혈관계 질환이 가장 많은 부분을 차지하고 있는데, 질환 사망자의 약 3/4은 당뇨 합병증에 의한 사망자이며, 심혈관계 합병증에 의한 사망 위험도 또한 당뇨 유병기간이 10년 증가할 때마다 24%씩 증가하는 것으로 보고되었다. 당뇨환자는 정상인에 비해 관상동맥 질환의 유병률이 2배나 높고 말초혈관질환에 대한 유병률은 약 3배 이상인 것으로 보고되었으며, 당뇨병에서 이러한 죽상 동맥경화를 일으키는 원인으로는 고혈당, 지질대사이상, 고인슐린혈증, 고혈압, 혈액응고 기전의 변화 등 다양하게 알려져 있다. 이러한 여러 합병증들은 개개인의 삶의 질 저하뿐만 아니라 사회/경제적인 손실 역시 막대한 실정이다.The characteristics and problems of diabetes in Korea are the fact that young diabetics in their 30s and 40s are rapidly increasing in Korea, unlike in the West where diabetes is mainly caused by the elderly population. Diabetes mellitus, the longer the disease, chronic complications due to blindness, end stage renal failure, neurological disease, lower extremity and infectious diseases. In particular, cerebrovascular disease and cardiovascular disease account for the largest portion of diabetes complications. About 3/4 of the disease deaths are caused by diabetes complications, and the risk of death from cardiovascular complications also increases the duration of diabetes for 10 years. It is reported to increase by 24% each time. Diabetic patients have a two-fold higher prevalence of coronary artery disease and a three-fold higher prevalence of peripheral vascular disease than normal patients. , Hypertension, changes in blood coagulation mechanisms are known. Many of these complications are not only degrading the quality of life of individuals but also socio-economic losses.
당뇨병의 95% 이상을 차지하는 제 2형 (인슐린 비의존형) 당뇨병의 병인은 두 가지 원인, 즉 인슐린 분비장애 및 인슐린 저항성의 복합 장애로 알려져 있다. 즉 당뇨병은 이 복합적인 장애로 인해 만성 고혈당 증상을 보이는 질환이다. 인슐린 분비장애란 혈당 농도에 따라 췌장의 베타세포에서 적절한 양의 인슐린이 분비되지 않는 상황을 말하며, 이는 인슐린을 분비하는 베타세포의 양적인 감소나 기능적인 분배장애를 모두 포함한다. 한편, 인슐린 저항성이란 분비된 인슐린이 혈류를 타고 표적장기에 도달했으나 그 표적세포에서 인슐린 작용 및 민감성이 저하된 상황을 의미하는데, 일반적으로 세포막 수용체 결합 후의 신호전달장애로 생각되며, 그 원인으로 유전적인 소인, 비만, 육체적 활동저하 및 고혈당 또는 이상지질혈증 등이 있다. 여기서 중요한 사실은 이 두 가지 병인이 서로 맞물려 있다는 점이다. 즉, 인슐린 저항성이 있으면 저항성을 극복하기 위해 더 많은 양의 인슐린이 분비되어야 하고, 반대로 인슐린 분비가 충분하지 않아 생긴 고혈당 자체가 다시 인슐린 저항성을 악화시킬 수 있다는 것이다.The etiology of type 2 (insulin-independent) diabetes, which accounts for more than 95% of diabetes, is known to be a combined disorder of two causes: insulin secretion disorder and insulin resistance. Diabetes mellitus is a chronic hyperglycemia due to this complex disorder. Insulin secretion disorder refers to a situation in which an appropriate amount of insulin is not secreted from the beta cells of the pancreas according to the blood glucose level, which includes both a quantitative decrease in insulin secreting beta cells and a functional distribution disorder. On the other hand, insulin resistance refers to a situation in which secreted insulin reaches the target organ through the bloodstream, but the action and sensitivity of insulin is decreased in the target cell, which is generally considered to be a signal transduction disorder after cell membrane receptor binding. Predisposition, obesity, decreased physical activity and hyperglycemia or dyslipidemia. The important thing here is that these two etiologies are interlocked. In other words, if insulin resistance is required, more insulin must be secreted to overcome resistance, and conversely, hyperglycemia caused by insufficient insulin secretion may worsen insulin resistance again.
청국장은 중요한 조미료일 뿐 아니라 영양소의 공급원으로서 대두 발효 숙성 중에 바실러스 서브틸러스(Bacillus subtilis)가 생산하는 효소에 의해서 독특한 풍미를 내는 동시에 대두의 당질과 단백질이 분해되어 가용성 질소화합물 펩톤, 폴리펩타이드, 아마이드 등과 끈끈한 점액질 물질이 생성되어 식품적 가치를 향상시킨다. 청국장 발효과정 중 콩 속에 함유된 이소플라본, 피틴산, 사포닌, 트립신 저해제, 토코페롤, 불포화지방산, 식이섬유 및 올리고당 등의 각종 생리활성물질과 항산화물질 및 혈전용해 효소를 다량 함유하고 있기 때문에 기능성 식품으로 그 중요성이 재조명되고 있다.Cheonggukjang is not only an important seasoning, but also a source of nutrients. It has a unique flavor by enzymes produced by Bacillus subtilis during fermentation of soybeans. Sticky mucous substances such as amides are produced to improve food value. It is a functional food because it contains a large amount of bioactive substances such as isoflavone, phytic acid, saponin, trypsin inhibitor, tocopherol, unsaturated fatty acid, dietary fiber and oligosaccharide, and antioxidants and thrombolytic enzymes contained in soybean during fermentation process. Its importance is being reexamined.
청국장은 혈전용해, 골다공증 예방, 고혈압, 동맥경화 예방, 혈액순환 촉진 및 혈중 알코올 농도 저하 등의 효과가 있는 것으로 알려져 있다. 이처럼 우수한 청국장의 이용가치와 효율을 증대하고 심한 불쾌취를 개선하기 위하여 다양한 기능성 소재를 첨가하여 청국장을 발효하였고, 효소적 처리에 의한 단백질을 유리 아미노산, 올리고펩타이드, 저분자 단백질로 변형하여 각각 원래 단백질에서 분해 후 처음과 다른 생리활성을 지니게 됨으로써 기능성을 향상시키려는 연구가 많이 시도되고 있다. Cheonggukjang is known to be effective in preventing thrombosis, osteoporosis, hypertension, atherosclerosis, promoting blood circulation and lowering blood alcohol concentration. Cheonggukjang was fermented by adding various functional materials in order to increase the use value and efficiency of such excellent Cheonggukjang and to improve severe unpleasant odor.The protein by enzymatic treatment was transformed into free amino acids, oligopeptides and low molecular weight proteins Many studies have been attempted to improve functionality by having different physiological activities after the first decomposition.
청국장은 특유의 점질성 조직감을 가지는 우리나라 전통 콩 발효식품으로서 단기간에 제조가능하며 영양적, 경제적으로 가장 효과적인 콩 섭취방법으로 인정되고 있다. 대부분의 콩 발효식품은 콩을 발효시키는 과정 중 콩 속에 함유되어 있는 이소플라본 및 유용성분의 배당체(glycoside)가 비배당체(aglycone) 형태로 변화하여 콩 자체보다 높은 생리활성을 나타내는 것으로 밝혀지고 있으며, 필수아미노산, 비타민 B1, B2, 나이아신, 판토텐산 등의 함량 및 각종 효소가 풍부하게 함유되어있다. 이러한 청국장은 단백질과 비타민의 중요한 공급원이 될 뿐만 아니라 청국장균의 정장효과, 섬유질의 변비예방효과, 발암물질과 콜레스테롤의 체외 배출효과, 점질물(mucin)의 알코올 흡수에 의한 해장효과, 사포닌의 혈관강화, 혈액순환 촉진 및 젖산분해효과, 레시틴의 뇌세포 노화와 치매 및 고혈압과 동맥경화 예방 효과 등이 보고되고 있다. 또한 종래 문헌에서 콩이 시험관법 (in vitro)에서 탄수화물 소화속도를 지연시켰으며, 콩 섭취 후 혈당 증가 완화를 보고하였다. Cheonggukjang is a Korean traditional soybean fermented food with a unique viscous texture and can be produced in a short period of time. Most fermented soybeans have been found to have higher physiological activity than soybeans because the glycosides of isoflavones and useful ingredients in the soybeans are changed into aglycone forms. It is rich in essential amino acids, vitamins B1, B2, niacin, pantothenic acid, and various enzymes. Cheonggukjang is not only an important source of protein and vitamins, but also the suiting effect of Cheongguk coli, the constipation prevention effect of fiber, the extracorporeal effect of carcinogens and cholesterol, the haematological effect of alcohol absorption of mucin, and the vascular strengthening of saponin. In addition, the blood circulation promoting and lactic acid degradation effect, lecithin brain cell aging and dementia, hypertension and atherosclerosis prevention effect has been reported. In addition, in the literature, soybeans delayed carbohydrate digestion rate in vitro, and reported a decrease in blood glucose increase after soybean ingestion.
홍삼은 수삼을 증숙한 후 건조하여 갈변화, 사포닌 및 아미노산 등의 품질변화를 거치게 된다. 인삼과 홍삼의 효능이 과학적으로 인정되고 있다. 지금까지 홍삼에 관한 연구는 연근별 추출법, 향기성분의 변화, 사포닌 조성 및 함량 등 많은 연구결과가 있으며 주로 사포닌 성분을 비롯하여 비사포닌 성분, 펩타이드, 전분성 다당체에 관한 연구가 보고되었다. 홍삼에 대한 약효와 효능을 점차 약리 및 임상학적인 면에서 과학적으로 입증되었고, 홍삼이 의약품은 물론 건강식품으로도 널리 인정받게 되어 수요층의 기호변화에 따라 이용과 가공방법도 점차 다양하게 개발되고 있다.Red ginseng is steamed and dried to undergo quality changes such as browning, saponin and amino acids. The efficacy of ginseng and red ginseng is scientifically recognized. Until now, there have been many studies on red ginseng extracts, lotus root extracts, scent components, saponin composition and content, and mainly researches on saponins, non-saponins, peptides, and starch polysaccharides. The efficacy and efficacy of red ginseng has been scientifically proven in pharmacological and clinical terms, and red ginseng is widely recognized as a medicine and health food, and its use and processing methods are gradually being developed according to the changing preferences of demand groups.
홍삼 (Red ginseng)은 인삼 (Pannax ginseng Nees)을 증기로 쪄서 건조시킨 것으로서 주로 자양강장제 (tonic)로 이용되는데, 노화억제, 면역증강, 항스트레스 작용 및 항암작용 등의 약리효과가 알려져 있다. 또한 최근 홍삼의 효과 중 일부는 홍삼의 항산화기능에 의한 것이라는 연구결과들도 있다. 당뇨병 상태에서는 산화적 스트레스가 증가하며 당뇨합병증이 증가되어 당뇨를 더욱 악화시킬 수 있으므로, 항산화기능을 가진 홍삼은 당뇨 합병증 예방 및 치료에 효과적일 것으로 여겨진다.
Red ginseng (Red ginseng) is steamed and dried by ginseng (Pannax ginseng Nees) is mainly used as a tonic nutrient (tonic), pharmacological effects such as anti-aging, immune enhancement, anti-stress and anti-cancer effects are known. In addition, some of the effects of red ginseng have recently been attributed to the antioxidant function of red ginseng. In diabetic state, oxidative stress increases and diabetic complications increase, which may worsen diabetes. Therefore, red ginseng with antioxidant function is considered to be effective in preventing and treating diabetic complications.
본 발명의 목적은 야채 육수에서 불린 콩을 삶아서 숙성시켜 건조시킨 청국장에 홍삼을 혼합하여 즉석에서 끓여 먹을 수 있는 간편하고 청국장의 맛을 그대로 살려서 즉석에서 신속하게 요리할 수 있는 홍삼 청국장의 제조를 위한 최적의 홍삼 전처리 방법을 제공하고, 이를 이용한 홍삼 청국장의 제조방법을 제공하며, 홍삼 청국장을 함유하는 항당뇨 기능성 식품을 제공하는 것이다.An object of the present invention is to mix the red ginseng in boiled soybeans called vegetable broth to aging and dried to make red ginseng Cheonggukjang that can be cooked quickly on the fly by using the simple and simple taste of Cheonggukjang It provides an optimal red ginseng pretreatment method, provides a manufacturing method of red ginseng Cheonggukjang using the same, and provides an anti-diabetic functional food containing red ginseng Cheonggukjang.
본 발명은 물 100 중량부에 표고버섯 20 중량부, 양파 20 중량부, 다시마 20 중량부 및 멸치 10 중량부를 혼합하여 삶아서 야채 육수를 제조하는 단계; 청국장을 제조하기 위한 콩을 세척한 후 상기 야채 육수에서 4 내지 16시간 불리는 단계; 가마솥에 불린 콩을 삶아서 황톳방에서 40 내지 60℃에서 24 내지 48시간 숙성시키는 단계; 건조실에서 10 내지 20시간 건조시키는 단계; 상기 건조시킨 청국장 90 내지 98 중량%에 홍삼 2 내지 10 중량%를 혼합하는 단계로 이루어진 것이다.The present invention comprises the steps of mixing 20 parts by weight of shiitake mushrooms, 20 parts by weight of onion, 20 parts by weight of kelp and 10 parts by weight of anchovy to prepare vegetable broth; Washing the soybeans for producing the soybean paste after 4-16 hours in the vegetable broth; Boiled soybeans in the cauldron and aged for 24 to 48 hours at 40 to 60 ℃ in the yellow clay; Drying in a drying room for 10 to 20 hours; 90 to 98% by weight of the dried Cheonggukjang consisting of 2 to 10% by weight of mixing.
본 발명에 따라 제조된 홍삼 청국장은 야채 육수에서 불린 콩을 삶아서 숙성시켜 건조시킨 청국장에 홍삼을 혼합하여 즉석에서 끓여 먹을 수 있는 간편한 청국장이며 청국장의 맛을 그대로 살려서 즉석에서 신속하게 요리할 수 있는 효과가 있다. 본 발명에 따라 제조된 홍삼 청국장은 기능성 강화되고 불쾌취가 감소되어 다양한 식품 소재로 활용이 가능하며, 혈당 감소효과를 나타내어 내당능 상태에서 뿐만 아니라 이미 제 2형 당뇨가 발병된 후에도 혈당조절에 유효하여 장기간의 혈당 조절 및 안정적 유지에 그 효과가 뛰어나고, 심혈관계 질환과 제 2형 당뇨에 수반되는 합병증 예방에 효과가 있으며, 이상지질혈증 및 심혈관 관련 합병증 예방에 효과가 있고, 대사관련 효소활성의 조절, 항산화 방어기전 개선 및 간 기능 향상에도 효과가 있어 이를 통해 인슐린 민감도를 향상시켜해 췌장의 기능을 보호하고 지질대사를 조절함으로써 공복혈당 조절 및 당뇨 합병증의 예방에 기여할 수 있어, 기능성 식품 산업상 매우 유용한 발명인 것이다.Red ginseng Cheonggukjang prepared according to the present invention is a simple Cheonggukjang that can be boiled and eaten immediately by mixing red ginseng in boiled soybeans mixed with boiled soybeans in vegetable broth and dried. There is. Red ginseng Cheonggukjang prepared in accordance with the present invention is functionally enhanced and reduced unpleasant odor can be used as a variety of food materials, exhibiting a blood sugar reducing effect is effective in blood sugar control not only in the state of glucose tolerance but also after the development of type 2 diabetes It is effective for long-term blood sugar control and stable maintenance, prevents complications associated with cardiovascular diseases and type 2 diabetes, prevents dyslipidemia and cardiovascular complications, and regulates metabolic related enzyme activity. In addition, it is effective in improving antioxidant defense mechanisms and liver function, thereby improving insulin sensitivity, thereby protecting pancreatic function and controlling lipid metabolism, thereby contributing to regulating fasting blood sugar and preventing diabetes complications. It is a useful invention.
본 발명은 물 100 중량부에 표고버섯 20 중량부, 양파 20 중량부, 다시마 20 중량부 및 멸치 10 중량부를 혼합하여 삶아서 야채 육수를 제조하는 단계; 청국장을 제조하기 위한 콩을 세척한 후 상기 야채 육수에서 4 내지 16시간 불리는 단계; 가마솥에 불린 콩을 삶아서 황톳방에서 40 내지 60℃에서 24 내지 48시간 숙성시키는 단계; 건조실에서 10 내지 20시간 건조시키는 단계; 상기 건조시킨 청국장 90 내지 98 중량%에 홍삼 2 내지 10 중량%를 혼합하는 단계; 및 파우치 형태로 보관하는 단계로 이루어진 것을 특징으로 하는 5분 즉석 홍삼 청국장의 제조방법에 관한 것이다.The present invention comprises the steps of mixing 20 parts by weight of shiitake mushrooms, 20 parts by weight of onion, 20 parts by weight of kelp and 10 parts by weight of anchovy to prepare vegetable broth; Washing the soybeans for producing the soybean paste after 4-16 hours in the vegetable broth; Boiled soybeans in the cauldron and aged for 24 to 48 hours at 40 to 60 ℃ in the yellow clay; Drying in a drying room for 10 to 20 hours; Mixing 2-10 wt% of red ginseng with 90 to 98 wt% of the dried Cheonggukjang; And it relates to a manufacturing method of instant red ginseng Cheonggukjang characterized in that it consists of a step of storing in the form of a pouch.
본 발명의 즉석 홍삼 청국장은 파우치 형태로 보관되며 15g, 30g, 60g, 120g 및 240g 중에서 선택된 형태로 보관되는 것을 특징으로 한다.The instant red ginseng Cheonggukjang of the present invention is stored in a pouch form, characterized in that it is stored in a form selected from 15g, 30g, 60g, 120g and 240g.
본 발명은 물 100 중량부에 표고버섯 20 중량부, 양파 20 중량부, 다시마 20 중량부 및 멸치 10 중량부를 혼합하여 삶아서 야채 육수를 제조하는 단계; 청국장을 제조하기 위한 콩을 세척한 후 물에서 4 내지 16시간 불리는 단계; 가마솥에 불린 콩을 삶아서 황톳방에서 40 내지 60℃에서 24 내지 48시간 숙성시키는 단계; 건조실에서 10 내지 20시간 건조시키는 단계; 상기 건조시킨 청국장 90 내지 98 중량%에 홍삼 2 내지 10 중량%을 혼합한 다음 상기 혼합된 홍산 청국장 100 중량부에 별도로 상기 야채 육수 100 중량부를 혼합하여 제조하는 단계; 및 파우치 형태로 보관하는 단계 로 이루어진 것을 특징으로 하는 5분 즉석 홍삼 청국장의 제조방법에 관한 것이다.The present invention comprises the steps of mixing 20 parts by weight of shiitake mushrooms, 20 parts by weight of onion, 20 parts by weight of kelp and 10 parts by weight of anchovy to prepare vegetable broth; Washing the soybeans for the production of Chungkookjang after 4-16 hours in water; Boiled soybeans in the cauldron and aged for 24 to 48 hours at 40 to 60 ℃ in the yellow clay; Drying in a drying room for 10 to 20 hours; Mixing 2 to 10 wt% of red ginseng to 90 to 98 wt% of the dried Cheonggukjang and then mixing 100 parts by weight of the vegetable broth separately to 100 parts by weight of the mixed Hongsan Cheonggukjang; And it relates to a production method of instant red ginseng Cheonggukjang, characterized in that consisting of a step of storing in the form of pouch.
홍삼은 인삼을 증숙하면 홍갈색으로 변하고 그것을 건조한 것으로 색이 홍색으로 변하여 홍삼이 된다. 인삼은 건강 식품과 보약으로 널리 이용하여 왔고 인체에 대한 약리 효능이 인정되고 있다. 인삼의 약리 효능은 주로 사포닌에 의한 것으로 항산화, 항염증, 면역기능 증진, 항 궤양, 항종양, 항 곰팡이, 및 항바이러스, 신경보호, 암예방, 불안완화, 혈당저하 등의 생리활성 기능이 있다. 인삼과 홍삼 성분은 인체에 해가 전혀 없는 안전한 것이며 흡수량이 많을수록 사람의 건강에 미치는 면역증강 및 보양의 효과가 상승하는 것으로 예상되며 각종 성인병 예방에 도움을 주며 인삼과 홍삼 성분을 통한 건강 증진의 효과를 얻을 수 있는 이점이 있으나 흡수율은 사람마다 약간의 차이는 있을 수 있고 섭취하는 사람에 따라 나타나는 효과에 관한 차이를 분석한 결과 장내에 있는 인삼성분을 흡수하는 효소의 유무와 함유량에 의해 체내 흡수에 차이가 있다. Red ginseng turns reddish brown when steamed, and it turns red to red ginseng. Ginseng has been widely used as a health food and medicine, and its pharmacological effects on the human body are recognized. The pharmacological efficacy of ginseng is mainly due to saponins, and it has antioxidant, anti-inflammatory, immune function enhancement, anti-ulcer, anti-tumor, anti-fungal, and anti-viral, neuroprotective, cancer prevention, anxiolytic and hypoglycemic functions. . Ginseng and red ginseng are safe and harmless to the human body. The more the absorption, the more effective the effect of immunity enhancement and rehabilitation on the health of human is expected. It helps to prevent various adult diseases and the effect of health promotion through the ingredients of ginseng and red ginseng Although there is an advantage in that the absorption rate may vary slightly from person to person, the analysis of the difference in effect according to the person ingested, according to the presence and content of enzymes that absorb the ginseng component in the intestine There is a difference.
본 발명은 홍삼을 청국장에 혼합하여 제조된 5분 즉석 홍삼 청국장 조성물에 관한 것이다. 홍삼이 함유한 유효성분이 체내에 흡수되어 효과를 높이기 위한 가장 적당한 방법이 발효이며 청국장에 함유된 효소균에 의해 홍삼의 유효성분들이 분해된 상태로 섭취되었을 때 홍삼성분의 유기영양분이 체내로 흡수가 용이하다.The present invention relates to a five-minute instant red ginseng Cheonggukjang composition prepared by mixing red ginseng in Cheonggukjang. Fermentation is the most suitable method to enhance the effects of red ginseng absorbed into the body. When the red ginseng is ingested with the active ingredients of red ginseng, the organic nutrients of red ginseng are absorbed into the body. It is easy.
본 발명에 따라 제조된 홍삼 청국장은 야채 육수에서 불린 콩을 삶아서 숙성시켜 건조시킨 청국장에 홍삼을 혼합하여 즉석에서 끓여 먹을 수 있는 간편한 청국장이며 청국장의 맛을 그대로 살려서 즉석에서 신속하게 요리할 수 있다.
The red ginseng Cheonggukjang prepared according to the present invention is a simple Cheonggukjang that can be boiled and eaten instantly by mixing red ginseng in boiled soybeans mixed with boiled soybeans in vegetable broth and dried.
실시예 1: Example 1:
물 10리터에 표고버섯 2kg, 양파 2kg, 다시마 2kg 및 멸치 1kg를 혼합하여 삶아서 야채 육수를 제조한다. 청국장을 제조하기 위한 콩을 세척한 후 상기 야채 육수에서 4 내지 16시간 불린 다음 가마솥에 불린 콩을 삶아서 황톳방에서 40 내지 60℃에서 24 내지 48시간 숙성시키고 건조실에서 10 내지 20시간 건조시킨다. 건조시킨 청국장 97 중량%에 홍삼 3 중량%를 혼합하여 5분 즉석 홍삼 청국장을 제조한다.
A vegetable broth is prepared by mixing 2 kg of shiitake mushrooms, 2 kg of onions, 2 kg of kelp and 1 kg of anchovies in 10 liters of water. After washing the soybeans for producing Cheonggukjang, soaked in the vegetable broth for 4 to 16 hours, and then boiled soybeans in the cauldron, aged for 24 to 48 hours at 40 to 60 ℃ in Hwangwangbang and dried for 10 to 20 hours in a drying room. Red ginseng Cheonggukjang is prepared by mixing red ginseng 3% by weight with 97% by weight of dried Cheonggukjang.
실시예 2: Example 2:
물 10리터에 표고버섯 2kg, 양파 2kg, 다시마 2kg 및 멸치 1kg를 혼합하여 삶아서 야채 육수를 제조한다. 청국장을 제조하기 위한 콩을 세척한 후 물에서 4 내지 16시간 불린 다음 가마솥에 불린 콩을 삶아서 황톳방에서 40 내지 60℃에서 24 내지 48시간 숙성시키고 건조실에서 10 내지 20시간 건조시킨다. 건조시킨 청국장 97 중량%에 홍삼 3 중량%를 혼합하여 상기 혼합된 홍산 청국장 10kg에 별도로 상기 야채 육수 10kg을 혼합하여 5분 즉석 홍삼 청국장을 제조한다.
A vegetable broth is prepared by mixing 2 kg of shiitake mushrooms, 2 kg of onions, 2 kg of kelp and 1 kg of anchovies in 10 liters of water. After washing the soybeans for producing the Cheonggukjang, soaked in water for 4 to 16 hours, and then boiled soybeans in the cauldron are aged for 24 to 48 hours at 40 to 60 ℃ in Hwangwangbang and dried in a drying room for 10 to 20 hours. 3 wt% of red ginseng was mixed with 97 wt% of dried Cheonggukjang, and 10kg of the vegetable broth was separately mixed with 10kg of the mixed Hongsan Cheonggukjang to prepare instant red ginseng Cheonggukjang for 5 minutes.
Claims (3)
청국장을 제조하기 위한 콩을 세척한 후 물에서 4 내지 16시간 불리는 단계;
가마솥에 불린 콩을 삶아서 황톳방에서 40 내지 60℃에서 24 내지 48시간 숙성시키는 단계; 건조실에서 10 내지 20시간 건조시키는 단계;
상기 건조시킨 청국장 90 내지 98 중량%에 홍삼 2 내지 10 중량%을 혼합한 다음 상기 혼합된 홍산 청국장 100 중량부에 별도로 상기 야채 육수 100 중량부를 혼합하여 제조하는 단계; 및
파우치 형태로 보관하는 단계로 이루어진 것을 특징으로 하는 5분 즉석 홍삼 청국장의 제조방법.
Preparing a vegetable broth by mixing 20 parts by weight of shiitake mushroom, 20 parts by weight of onion, 20 parts by weight of kelp, and 10 parts by weight of anchovy by mixing water with 100 parts by weight of water;
Washing the soybeans for the production of Chungkookjang after 4-16 hours in water;
Boiled soybeans in the cauldron and aged for 24 to 48 hours at 40 to 60 ℃ in the yellow clay; Drying in a drying room for 10 to 20 hours;
Mixing 2 to 10 wt% of red ginseng to 90 to 98 wt% of the dried Cheonggukjang and then mixing 100 parts by weight of the vegetable broth separately to 100 parts by weight of the mixed Hongsan Cheonggukjang; And
5 minutes instant red ginseng Cheonggukjang, characterized in that consisting of a step of storing in the form of a pouch.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120038445A KR101387825B1 (en) | 2012-04-13 | 2012-04-13 | process of manufacturing a bean sorce |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120038445A KR101387825B1 (en) | 2012-04-13 | 2012-04-13 | process of manufacturing a bean sorce |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130115794A KR20130115794A (en) | 2013-10-22 |
KR101387825B1 true KR101387825B1 (en) | 2014-04-22 |
Family
ID=49635180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120038445A KR101387825B1 (en) | 2012-04-13 | 2012-04-13 | process of manufacturing a bean sorce |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101387825B1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050079815A (en) * | 2004-02-06 | 2005-08-11 | 박수미 | Process of manufacturing well-being soybean korean soup |
KR20060117151A (en) * | 2005-05-13 | 2006-11-16 | 최익택 | Method of fermented soybeans |
KR20070095595A (en) * | 2006-03-22 | 2007-10-01 | 권오태 | Red ginseng cheonggukjang |
KR20110138492A (en) * | 2010-06-21 | 2011-12-28 | (주)비알글로벌 | Manufacturing process of scentless fast-fermented soybean paste vegetable of sprout and ginseng steamed red |
-
2012
- 2012-04-13 KR KR1020120038445A patent/KR101387825B1/en not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050079815A (en) * | 2004-02-06 | 2005-08-11 | 박수미 | Process of manufacturing well-being soybean korean soup |
KR20060117151A (en) * | 2005-05-13 | 2006-11-16 | 최익택 | Method of fermented soybeans |
KR20070095595A (en) * | 2006-03-22 | 2007-10-01 | 권오태 | Red ginseng cheonggukjang |
KR20110138492A (en) * | 2010-06-21 | 2011-12-28 | (주)비알글로벌 | Manufacturing process of scentless fast-fermented soybean paste vegetable of sprout and ginseng steamed red |
Also Published As
Publication number | Publication date |
---|---|
KR20130115794A (en) | 2013-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guo et al. | The bioactive compounds and biological functions of Asparagus officinalis L.–A review | |
Wang et al. | A systematic review on the composition, storage, processing of bamboo shoots: Focusing the nutritional and functional benefits | |
Nasar‐Abbas et al. | Carob kibble: A bioactive‐rich food ingredient | |
CN102488281B (en) | Novel pure plant composite concentrated drinking liquid with blood sugar reducing effect, and preparation method thereof | |
JP2004159637A (en) | Dietary composition | |
Martín-Cabrejas | Legumes: an overview | |
KR101039640B1 (en) | Method for producing rice for reducing glucose using coating mixture of mulberry leaf extract and onion juice | |
KR102180204B1 (en) | Manufacturing method of Kimchi for preventing diabetes and alcohol-based liver damage | |
Huang et al. | Processing technologies, phytochemistry, bioactivities and applications of black ginseng-a novel manufactured ginseng product: A comprehensive review | |
CN105533446A (en) | Nutritious oatmeal with health-care effect and preparation method thereof | |
Santosh et al. | Application of bamboo in the food and pharmaceutical industry | |
CN104255882A (en) | Health-care fresh biscuit for preventing hyperlipidemia and manufacturing method thereof | |
KR20110014421A (en) | A nature spice | |
CN104187378A (en) | Blood sugar decreasing health noodles and preparation method thereof | |
CN107802770A (en) | Balance the Chinese medicine and health products of metabolic system radical cure early stage type II diabetes | |
KR20150053524A (en) | Dried Noodle Using Helianthus tuberosus and Dangjo Pepper and Their of Method | |
KR102550433B1 (en) | Brown rice nurungji for improvement of diabetes and Manufacturing method thereof | |
KR101387825B1 (en) | process of manufacturing a bean sorce | |
CN103583976B (en) | Yam taro corn noodle and producing method thereof | |
CN104186624A (en) | Health-care fresh cake with auxiliary hypoglycemic effect and making method thereof | |
Gafforov et al. | Pleurotus eryngii (DC.) Quél.; Pleurotus ostreatus (Jacq.) P. Kumm.-PLEUROTACEAE | |
KR20100102277A (en) | The grain syrup using a mugwort and a pumpkin and process for preparing thereof | |
CN103637095A (en) | Health-care pumpkin rice crust | |
KR20070013841A (en) | Manufacturing method of garlic snack | |
KR20140067272A (en) | The rice cake for mitigating diabetic and its manufacturing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |